Check out our most popular compounded medications! Get Started
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded suspension containing bupropion hydrochloride, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing bupropion are listed in tablet form. It is also a component of FDA-approved kits.
Liquid bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Bupropion is an aminoketone antidepressant and smoking cessation aid that compounding pharmacies prepare as oral capsules and liquids.
Bupropion is an aminoketone antidepressant. Its exact mechanism is unknown; it is a relatively weak inhibitor of norepinephrine and dopamine reuptake and does not act on serotonin reuptake or monoamine oxidase, which sets it apart from SSRIs. Manufactured bupropion hydrochloride is sold as immediate-release, sustained-release (Wellbutrin SR) and extended-release (Wellbutrin XL) tablets, as a hydrobromide salt (Aplenzin), and combined with dextromethorphan (Auvelity) or naltrexone (Contrave). Wellbutrin SR is FDA-approved for major depressive disorder in adults; Wellbutrin XL adds prevention of seasonal major depressive episodes. Zyban is discontinued, but generic bupropion SR tablets remain FDA-approved as an aid to smoking cessation. Prescribers may order bupropion compounded in a strength not manufactured for gradual titration, as an immediate-release liquid for someone who cannot swallow tablets, in a dye-free capsule, or combined with another active. Compounded bupropion preparations are not FDA-approved and require a prescription.
Bupropion carries the antidepressant class boxed warning: it increases the risk of suicidal thoughts and behaviors in children, adolescents and young adults, and anyone starting it should be watched for worsening mood or new suicidal thinking. Other label warnings include dose-related seizures, raised blood pressure, activation of mania or psychosis, angle-closure glaucoma, and serious allergic reactions including anaphylaxis and Stevens-Johnson syndrome. It should not be used by people with a seizure disorder, a current or past diagnosis of bulimia or anorexia, or those abruptly stopping alcohol, benzodiazepines, barbiturates or antiseizure drugs, and it must not be combined with monoamine oxidase inhibitors, linezolid or intravenous methylene blue. Bupropion inhibits CYP2D6, raising levels of metoprolol, nortriptyline, paroxetine, risperidone and flecainide; ticlopidine and clopidogrel raise bupropion exposure while ritonavir, efavirenz, carbamazepine and phenytoin lower it. It can cause false-positive urine amphetamine screens. Pregnancy registry data show no overall increase in malformations. Bupropion passes into milk at about 2 percent of the maternal dose; a drugs.com breastfeeding review notes rare infant seizure case reports and says needing bupropion is not a reason to stop nursing. For insomnia, dry mouth, nausea or headache, talk to your prescriber or pharmacist; seek care right away for a seizure, racing thoughts, a fast heartbeat or a rash with swelling.
Bupropion weakly inhibits dopamine and norepinephrine reuptake without serotonergic or MAO activity. It is rapidly absorbed, about 84 percent protein bound, and extensively metabolized, chiefly by CYP2B6 to hydroxybupropion; threohydrobupropion and erythrohydrobupropion form by carbonyl reduction. All three metabolites are active. Mean half-lives are about 21 hours for bupropion, 20 hours for hydroxybupropion, 33 hours for erythrohydrobupropion and 37 hours for threohydrobupropion; about 87 percent of a dose is recovered in urine, less than 1 percent unchanged. Peak time depends on release form (about 2 hours immediate-release, 3 hours SR, 5 hours XL per StatPearls), which matters when a compounded immediate-release capsule replaces an extended-release tablet. Labeled indications: Wellbutrin SR for major depressive disorder; Wellbutrin XL for major depressive disorder and prevention of seasonal major depressive episodes; bupropion SR (generic; Zyban brand discontinued) as an aid to smoking cessation treatment. Prescribers have ordered compounded bupropion for antidepressant-induced sexual dysfunction, ADHD, bipolar depression, obesity (in combination with naltrexone) and stimulant use disorder, off-label uses listed in StatPearls. Dosing and titration are per prescriber. Monitoring: suicidality and mood at initiation and dose changes, blood pressure before and during therapy (especially with nicotine replacement), seizure risk factors, and screening for bipolar disorder before starting. No therapeutic serum range exists. Not a controlled substance.
Shake the bottle well before every dose so the medication is evenly mixed. Measure with the oral syringe or dosing cup provided, using the milliliter markings, and never a kitchen spoon. Take it by mouth as your label directs. Rinse the syringe after use and recap the bottle.
Water-based suspensions are aqueous preparations. Under USP <795>, a preserved suspension usually carries a beyond-use date of up to 35 days at room temperature or refrigerated; an unpreserved one is refrigerated for up to 14 days. Oil-based suspensions are nonaqueous and may carry up to 90 days. Your label states storage and the beyond-use date. Keep out of reach of children and discard after that date.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take orally
